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Abstract
The human leukocyte antigen (HLA) complex on chromosome 6p21 has been unambiguously associated with multiple
sclerosis (MS). The complex features of the HLA region, especially its high genic content, extreme polymorphism, and
extensive linkage disequilibrium, has prevented to resolve the nature of HLA association in MS. We performed a family
based association study on the isolated population of the Nuoro province (Sardinia) to clarify the role of HLA genes in MS.
The main stage of our study involved an analysis of the ancestral haplotypes A2Cw7B58DR2DQ1 and A30Cw5B18DR3DQ2.
On the basis of a multiplicative model, the effect of the first haplotype is protective with an odds ratio (OR)=0.27 (95%
confidence interval CI 0.13–0.57), while that of the second is deleterious, OR 1.78 (95% CI 1.26–2.50). We found both class I
(A, Cw, B) and class II (DR, DQ) loci to have an effect on MS susceptibility, but we saw that they act independently from each
other. We also performed an exploratory analysis on a set of 796 SNPs in the same HLA region. Our study supports the claim
that Class I and Class II loci act independently on MS susceptibility and this has a biological explanation. Also, the analysis of
SNPs suggests that there are other HLA genes involved in MS, but replication is needed. This opens up new perspective on
the study of MS.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease which mostly
affects young people and which causes myelin destruction and
neuronal cells degeneration leading the patient to a progressive
disability. The disease has a preference for females and may
manifest relapsing or progressive forms. Although the picture of
genes involved in the susceptibility to MS is far to be completed,
the Human Leukocyte Antigen (HLA) complex on chromosome
6p21 has been unambiguously associated with MS [1–8].
HLA Class I and Class II genes code proteins which are central
in activating antigen-specific immune responses. HLA Class I and
Class II proteins bind antigenic peptides and display them on the
cell surface for recognition by CD8+or CD4+T-lymphocytes,
respectively, thus activating the cellular immune response [9].
Many of the HLA associated disease are believed to be
autoimmune [10]. Indeed among mature lymphocytes, there are
many potential autoreactive T and B cells [11]. In MS, improper
activation of the immune system in response to myelin antigens is
thought to be a major cause of inflammatory deyemelination.
Initially the association between HLA and MS was studied in HLA
Class I loci [12]. However, the attention turned to HLA Class II
loci as Class I loci were presumed to be secondary to Linkage
Disequilibrium (LD) with disease predisposing Class II alleles [13–
15]. Consistent results were found particularly for HLA-DRB1 and
HLA-DQB1. Indeed, the HLA-DR2 haplotype is one of the most
reproduced findings in the genetics of the Major Histocompati-
bility Complex (MHC) [3,5,6,13,16–18]. The HLA-DRB1*1501
allele, encompassed within the DR2 specificity, was found to be
strongly associated with MS in North American, in North
European Caucasian patients and in White Brazilians from Rio
de Janeiro and from Sao Paolo [13,19–23], while the DRB1*1503
allele has been associated with MS in Mulattos from Sao Paolo
and in Afro-American patients [21,24], but not in Afro-Brazilians
from Rio de Janeiro [19,25]. The DRB1*0301, and DRB1*0401
alleles were seen to be over-represented in Sardinians [26]. In
Turkish patients and in those coming from the Canary Islands, an
association was reported between the HLA-DRB1*04 allele group
and the disease [27]. The DRB1-17 allele has long been known to
be associated with susceptibility in the Swedish population [28]
and this was confirmed in Canadians [29]. A recent pooled
analysis [30] of the past 30 years of research on the role of MHC
in multiple sclerosis, highlights the preeminent role of the extended
haplotype defined by HLA-DRB1*1501 in MS. Two other
ancestral haplotypes containing HLA-DR3 and HLA-DR4 also
appear to play a role in MS susceptibility, although the effect of
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DR2 haplotypes.
Recently, the possible importance of HLA Class I genes in MS
susceptibility has been reinvestigated and genetic association has
been found. In Swedish patients, HLA-A3 was positively associated
to MS, independently on DRB1-15, while a negative association
was found for HLA-A2 [31,32]. The same association was reported
in Tasmanians [33]. In Norwegian sporadic MS patients
association was seen with HLA-A, HLA-B [34]. Indeed, the HLA-
A3 gene was found to increase the risk conferred by the HLA-
DRB1*1501 haplotype. Mapping studies from the UK and the US
identified a significant protective effect of HLA-CW5 [17].
Clearly, these results indicated that one allele for any given HLA
locus, tends to exhibit different behaviours and confer resistance or
susceptibility in response to different environmental or genetic
backgrounds; within the DRB1 gene there appears to be evidence
for allelic heterogeneity particularly in non European populations
[35]. This may help to refine the conceptual model of MS
pathogenesis and suggests the possibility that a complex trans DRB1
allelic interactions may determine the balance between suscepti-
bility and resistance [20].
Despite the numerous studies carries out so far, the complex
features of HLA region, especially its high genic content, extreme
polymorphism and extensive LD, has so far prevented the
resolution of the nature of HLA association in MS.
Here we present the results of a study on the association of HLA
and MS carried out in the Nuoro province of Sardinia.
The Mediterranean island of Sardinia, and in particular the
Nuoro province, is well suited to identify HLA loci associated with
MS. Indeed, it has an MS prevalence four/five times higher than
the Italian mainland, registering 1 case per 500 inhabitants [36].
Isolation, genetic drift and perhaps selection have contributed to a
genetic differentiation, and the HLA loci distribution is charac-
terised by a very high number of rare haplotypes and by a small
number of very frequent haplotypes [37]. Seven of them have a
frequency higher than 0.85% [38] and thus are ancestral
haplotypes. The two most frequent ancestral haplotypes are
A30Cw5B18DR3DQ2 (14.6%), which has the strongest LD
observed in the world [39], and A2Cw7B58DR2DQ1 (6.0%). Since
ancestral haplotypes are highly conserved at least between HLA-B
and DR, they can be used as markers for all polymorphisms within
the entire MHC region and allow mapping studies of known and
unknown genes without requiring assumptions as to the mecha-
nisms involved [40]. More information on ancestral haplotypes is
given in the supporting material S1.
The main aim of our work is to identify which of the above
mentioned alleles of HLA ancestral haplotypes confer genetic
susceptibility/protection to MS in the population of the Nuoro
province, Central East Sardinia. A second aim is to detect variants
associated to MS independently on HLA loci A, B, Cw, DR and DQ
via an exploratory analysis on a set of 796 Single Nucleotide
Polymorphisms (SNPs) located in the HLA region.
Materials and Methods
Study Design
We carried out a family based association study. The study
sample consisted of 628 individuals belonging to 213 small groups,
which we called ‘‘nuclei’’. Each nucleus was ascertained around an
MS case, or proband, extracted from the MS register running in
the province of Nuoro since 1995. Diagnoses of MS were in
accord with Poser’s criteria for clinical definite MS [41]. All
individuals gave informed consent to their inclusion in this study,
which was approved by the local Ethics Committee. The nuclei
were classified into 3 types: type-1 nuclei consisting of a proband
and of his/her parents, plus occasionally the proband’s siblings
(n=69); type-2 nuclei consisting of the proband, of his/her spouse
and of their children (n=28), and type-3 nuclei consisting of a
proband and of a corresponding unrelated control, matched by
village of origin (n=116). SNPs genotyping was performed at the
Centre National de Genotypage, Evry, France, while HLA typing
was done at ‘‘Centro di Tipizzazione Tissutale’’, Nuoro, Italy.
Typing and quality control procedures are described in the
supporting material S2.
Statistical Analysis
Pseudocases and pseudocontrols. To deal with different
types of trios, we adopted the same approach described in
Bernardinelli et al. [42] which we outline below.
In a classical trio study, an ascertained proband is genotyped
along with his/her parents to form a proband-parent trio (Type 1).
Our approach extends this design by including two further
ascertainment schemes before called ‘‘nuclei’’. In the first, a
proband is genotyped along his/her spouse and possibly their
offspring (Type 2). In the second, an isolated proband is recruited
into the study to act as an isolated case with a corresponding
controls, matched by village of origin (Type 3).
We regard a family-based association study as a special case of
matched case/control analysis, where each nucleus contributes
pseudocases and pseudocontrols. In type 1 nuclei, we define the
two pseudocases to be the two parental HLA haplotypes
transmitted to the proband and the two pseudocontrols to be
the remaining two parental HLA haplotypes. In type 2 nuclei, we
define the pseudocases to be the two HLA haplotypes found in the
proband and the pseudocontrols to be those found in the spouse.
We can also define pseudocases and pseudocontrols at a genotype
level, where the two transmitted haplotype form the pseudocase
genotype and the two untransmitted haplotypes the pseudocontrol
genotype. Likewise in type 2 and type 3 nuclei the genotype of the
proband acts as pseudocase genotype and that of the spouse/
population control as pseudocontrol genotype. We pool the three
types of nuclei into a joint analysis which looks for a phased
genotype of variants that are more (or less) frequent in the
pseudocase than in pseudocontrols. So, we perform the analysis at
a genotype (phased) level where the genotype is formed by two
haplotypes.
Haplotype reconstruction and missing genotype
data. Haplotypes reconstruction is done using a Bayesian
Monte Carlo approach. Briefly, given genotyping data at
multiple linked loci, we estimate the unobserved haplotypic
phase and impute any missing calls by combining information
about population haplotypic frequencies with information about
the neighbouring loci. Using Phase [43], we obtain all possible
haplotypic configurations, each with a weight assigned according
to a coalescent underlying population model, but without
considering the structure of the family. The weights are then
updated via evaluating the Mendelian consistency between the
different haplotype configurations of the parents and the genotype
of the child. In the extreme situation, the method gives a weight
equal to zero for the configurations which are not Mendelian
consistent with the observed child genotype and a weight equal to
1 when there is only one possible configuration which is consistent
with the child genotype. For type 2 trios, the presence of the child
has the important role of providing information that allows us to
reduce the number of possible configurations in the parents thus
reducing the uncertainty in haplotype reconstruction and missing
data imputation. For type 3 nuclei, however, weights are not
updated as there are no children. This reweighting procedure is
HLA and Multiple Sclerosis
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(GADA) software that allows outputting all the configurations of
the pseudocase and pseudocontrol genotype for each nucleus
along with its posterior weight. We call the output the
reconstruction table. Refer to our paper [42] for a formal
description of the approach and an example of reconstruction
table. The reconstruction table can be analyzed via unconditional
weighted logistic regression as suggested by Cordell [44]. Our
analysis does not maintain the matched design, and would be
conservative under population stratification.
We extended this approach to allow for missing genotype data.
When genotypes are missing, we exploit linkage disequilibrium in
the local region to impute missing genotype calls using information
from the neighbouring loci. Specifically, we include additional loci
in the haplotype, whose contribution to disease risk is not of
interest, but which provide information on missing genotypes of
interest. The set of haplotypes consistent with a given unphased
genotype is then expanded to include those with all possible
completions of a missing genotype, while maintaining Mendelian
consistency. This will attenuate the impact of biased missingness,
for example when a SNP is preferentially missing heterozygotes
among either cases or controls.
Analyses
Regression based association test. In the regression each
pseudocase genotype can be considered as an independently
observed response/covariate pair, where the response is 0 for
pseudocase and 1 for a pseudocontrol and the covariate represents
the wild type homozygote or the heterozygote or the mutant
homozygote genotype. The use of the weighting option in
packages such as STATA and R allows each configuration of
the pseudocase/pseudocontrol genotype for each nucleus to enter
in the logistic regression with a relative importance fixed by the
corresponding posterior weight. This allows us to take into account
the uncertainty in phase reconstruction and the imputation of
missing data.
We analysed the data by fitting regression models both to
investigate departure from the multiplicative model and to identify
the effect model best fitting the data, and to perform hypothesis
driven tests to study the association between HLA alleles and SNPs
variants with MS.
We started by modelling the relationship between MS and the
HLA genetics markers to try to underpin the transmission
inheritance model. We fitted the weighted regression model at a
genotype level by assuming the following genetic models: (a) not
assuming any model, (b) a dominant, (c) a recessive and (d)
multiplicative.
For fitting the model (a), we fitted a regression model to the
genotype considered as a categorical (3 levels) variable, for model
(b) we created a binary variable by aggregating the heterozygote
with the mutant homozygote, for model (c) we created a binary
variable by aggregating the wild type homozygote with the
heterozygote genotype, and for model (d) we included the
covariate representing the genotype (three categories) as a
continuous variable.
We used a Likelihood Ratio Test (LRT) to check the departure
from a multiplicative model (we compared model (d) with model
(a)). If the p-value for the LRT is statistically significant, then we
conclude that there is a departure from the multiplicative model.
In this case we fitted the regression model by assuming the
dominant and the recessive model and selecting the best model on
the basis of the Wald test measuring the goodness of fit.
For whichever purpose the model was fitted, we estimated a
parameter (log Odds Ratio - OR) measuring the effect of a given
genotype versus all the others on the risk of disease. We embedded
in the regression model a permutation scheme (permuting the
case/control label) that protects from the possibility that the
weighting scheme used in the regression does not rigorously
correspond to a likelihood of a specific model of the data. To
compute p-values (which we call empirical p-values), we applied a
permutation scheme to the Wald’s statistics of the genotype
specific odds ratio parameter, to the Wald test measuring the
goodness of fit of the model and to the likelihood ratio tests used to
check (a) the departure from a multiplicative model and (b) to
perform a conditional independent test (see below).
Independent Effect and Sole Variant Tests. Finally, we
performed two hypothesis driven related conditional tests
(independent effect and sole variant tests) to try to identify which
variant, or variants, is solely and independently associated with the
disease [45].
When we perform a sole variant test we compare a model
including both ‘everything else’ and the ‘particular variant’ with a
model including the ‘particular variant’. If the p-value for the LRT
is not statistically significant we conclude that the particular
variant is the ‘sole variant’, i.e. it is the only variant that matters.
When we perform an independent test we compare via LRT a model
in which ‘everything else’ and the ‘particular variant’ are included
with a model including ‘everything else’. If a p-value for the LRT
is statistically significant, then we conclude that this particular
variant is associated independently on everything else. In both
cases, ‘everything else’ refers to the local haplotypic background as
determined by the markers under study.
We also performed a conditional independence test between the
significant associated variants by comparing the model including
both variants and a model including just one of the variant. A
statistically significant p-value indicates that a variant is not
conditionally independent on the disease given the other variant.
The test compares via a LRT a model in which a variant that is
statistically significant and a model in which further variant(s) are
added. If the LRT is not statistically significant, this means that the
second variable is conditionally independent on the disease, given
the first one.
Studying the association between SNPs in the HLA region
and MS. The lack of SNP genotypes on all the individuals who
are genotyped for HLA loci (see supplementary methods) led us to
adopt a method that uses HLA loci as proxies in the association
analysis in order to impute the missing SNPs. We performed the
analysis using UNPHASED software [46].
This method estimates haplotype frequencies across all specified
markers, including the SNPs of interest and the tag HLA alleles.
However the model for disease risk includes an effect only for the
SNPs of interest. When the data include some individuals with
genotypes for all HLA and SNP markers, and others with genotypes
forthe HLAallelesonly,themethodusesa missingdata likelihood to
estimate the association for the SNPs of interest, using information
from the HLA alleles when the SNP genotype is missing.
In order to distinguish the association of SNPs from their
linkage disequilibrium with association HLA alleles, we performed
a conditional analysis allowing for the HLA association. Here the
disease model includes effects for both the SNPs of interest and the
HLA alleles, but only the SNP effects are tested [47]. Again, a
missing data likelihood is used to allow for both haplotype phase
uncertainty and missing SNP data.
Results
Structure of the family nuclei, % of missing genotype, number
of individuals genotyped for both HLA and SNPs in term of the
HLA and Multiple Sclerosis
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material.
Analysis of the ancestral haplotypes
The ancestral haplotypes reconstruction in the Nuoro popula-
tion shows that the A2Cw7B58DR2DQ1 haplotype has a frequency
of 4.3% while the A30Cw5B18DR3DQ2 haplotype has a frequency
of 15.2%. The frequencies of the alleles at each locus for every
ancestral haplotype are reported in the supporting material S3. On
the basis of a multiplicative model, the effect of the first haplotype
versus all the others is protective, OR 0.27(95% Confidence
Interval CI 0.13–0.57), while that of the second is deleterious, OR
1.78 (95% CI 1.26–2.50).
As to the effect model, the allele B18 is the only one showing a
statistically significant departure from a multiplicative model
(p=0.006). The recessive model is the best fitting model
(p=0.0001) on the basis of the Wald test. The empirical p-values
of the single locus marginal test show that for Class I loci, in the
protective haplotype, only Cw and B are significantly associated to
MS, while in the deleterious haplotype A, Cw, B are all associated
to the disease. For Class II loci, DR and DQ are significantly
associated with the disease both for the protective and the
deleterious haplotypes (Table 1).
We performed an analysis which aims at identifying which loci
composing the deleterious and protective haplotype, can solely
explain the association with the disease. We carried out on the
protective and the deleterious haplotype separately considered a sole
variant and independent test and a conditional independence test
to investigate which loci within Class I and Class II could be
considered as a single variant associated with the disease (Table 2).
For the protective haplotype in Class I, B58 is a sole variant
associated with MS; on the contrary, from the independence test
B58 turns out to be independently associated with MS given A2
Cw7 (p-value of 0.0004 of the LRT).
In Class II, the sole variant is DQ1(empirical p-value of 0.74)
and also DQ1 is independently associated with MS given DR2 (p-
value=0.001).
As for the deleterious haplotype, on the basis of the LRT we
identify B18 as being the sole variant in Class I loci. B18 is also
independently associated with MS given A30 Cw5. As for the
deleterious haplotype, DR2 turns out to be a sole variant, but it is not
independently associated to MS. The strong linkage disequilibri-
um between the DR3 and DQ2 alleles (D’=0.98, R
2=0.75) does
not allow us to identify which of the two loci is responsible of the
association (Table 2).
To further pinpoint the specific allele contributing to MS
susceptibility, a conditional independent test was carried out
between the sole variants identified within Class I loci and the sole
variant within Class II loci.
For the protective haplotype, DQ1 is not conditionally indepen-
dent on MS given B58 and B58 viceversa. For the deleterious
haplotype, the DR3 locus appears to be conditionally independent
on the disease given the B18 locus, while DR3 is not conditionally
independent on MS given B58 (Table 3).
Within each haplotype, we also estimated the effect in terms of
odds ratio of each sole variant in Class I adjusted for the effect of
the sole variant in Class II loci versus all the other variants in Class
I also adjusted for the effect of the sole variant in Class II loci, by
fitting a model including both the sole variant in Class I and the
sole variant in Class II.
In agreement with the conditional independent tests, within the
protective haplotype, both the loci B58 and DQ1 show a strong
protective statistically significant effect while within the deleterious
haplotype only the B18 locus show a statistically significant
deleterious effect. This further confirms that the DR3 locus is
conditionally independent on the disease given the B18 locus (for
details see supporting material S4).
Investigating the effect of all alleles at the B, DR and DQ
loci
We investigated the effect of the complete available set of alleles
for B, DR, DQ loci and only alleles belonging to the ancestral
haplotypes turned out to be significant (Table 4).
Since a strong association with an allele (for example protective)
can mask the association with another allele whose effect is
protective as well, we investigated the effect of the alleles other
than those composing the ancestral haplotypes by performing an
analysis that conditioned on a specific allele belonging to the
ancestral haplotype. Details on the conditioning method are given
in the supporting material S5. For the B locus, the effect of B58
emerges only after we condition on B18 and no other allele is
significant; for the DR locus, DR6 is significant, with a protective
effect, when conditioning on DR2 only and when conditioning on
both DR2 and DR3. Finally, conditioning on DQ2 (deleterious
allele) makes the deleterious association effect with both DQ3 and
DQ4 to be detected. DQ1 remains significant also when
conditioning on DQ2 (supporting material S5).
SNP analysis
We now report the results of our exploratory analysis using a
nominal significance level p,0.005 for unconditional tests. We
studied the association between MS and 796 SNPs by using the
program UNPHASED with the tag and missing options. We used
the tag option to overcome the discrepancy between the
individuals typed for HLA loci and the individuals typed for SNPs,
the latter being much less numerous than those typed for HLA.W e
specified as tag markers the HLA loci composing the ancestral
haplotypes which did not show a significant association with MS
after conditioning on the most strongly associated loci. More
specifically, we performed two analyses: (1) where tag markers are
HLA loci composing the protective ancestral haplotype
(A2,Cw7,DR2) and (2) where tag markers are HLA loci composing
the deleterious ancestral haplotype (A30,Cw5,DQ2). This choice
was motivated by two considerations (1) we did not want to
influence the association test for SNPs by choosing as tags the
SNPs which turned out significantly associated with MS (2) we
could not exclude that some SNPs associated with disease might be
in LD with the protective alleles and some in LD with the
deleterious allele. In each case we recoded each of the HLA loci
into a binary variable, indicating the presence of the allele present
on the extended protective (or deleterious) haplotype.
The analysis using the protective haplotype to predict missing
SNPs leads to signals of association with SNPs located in the
following genes: PSORS1C1 (Psoriasis susceptibility 1 candidate
1 - ENSG00000204540), TCF19 (Transcription factor 19 -
ENSG00000137310), BAT2 (HLA-B associated transcript 2 -
ENSG00000204469), BAT3 (HLA-B associated transcript 3 -
ENSG00000204463), NOTCH4 (Neurogenic locus notch homolog
protein 4 - ENSG00000204301), ITPR3 (Inositol 1,4,5-triphos-
phate receptor, type 3 - ENSG00000096433) and PACSIN1
(Protein kinase C and casein kinase substrate in neurons 1 -
ENSG00000124507).
The analysis using the deleterious haplotype to predict missing
SNPs leads to highlighting the same set of genes as the analysis with
the protective haplotype, and in addition BTNL2 (Butyrophilin-like
2 - ENSG00000204290), BAK1 (BCL2-antagonist/killer 1 -
ENSG00000030110) and HLA-DOB (Major histocompatibility
complex, class II, DO beta - ENSG00000204273), TAP2 (Trans-
HLA and Multiple Sclerosis
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The p-values of the null hypothesis of association are reported in the
supporting material S6.
We finally tested whether the effect seen in these SNPs was due
to the LD with the associated HLA alleles. For this purpose we
performed an analysis of the associated SNPs, conditioning on the
Table 1. A2Cw7B58DR2DQ1 protective haplotype and A30Cw5B18DR3DQ2 deleterious haplotype: genotype frequency of the allele
composing the haplotypes in pseudocases, pseudocontrols, Odds ratio (OR) and its 95% Confidence Interval (CI), p-value of the
Wald’s Test of association and empirical p-value computed under the multiplicative model.
Locus Genotypes Pseudocases N Pseudocontrols N OR 95% CI LRT p REG p LRT Empirical p
PROTECTIVE HAPLOTYPE: A2Cw7B58DR2DQ1
A 1.00E-01 9.90E-02 1.00E-01
X/X 117 98
X/2 72 91 0.80 0.63–1.04
2/2 19 19 0.65 0.39–1.08
Cw 7.10E-01 1.80E-02 3.80E-02
X/X 120.63 103.6
X/7 64 68.57 0.76 0.61–0.95
7/7 23.36 35.86 0.58 0.37–0.91
B 4.90E-01 1.30E-05 1.30E-05
X/X 193 168
X/58 15 35.66 0.33 0.20–0.55
58/58 0 4.34 0.11 0.04–0.30
DR 3.90E-01 9.25E-05 9.00E-05
X/X 162 135.5
X/2 44 63.34 0.54 0.39–0.73
2/2 2 9.19 0.28 0.15–0.54
DQ 2.00E-01 1.02E-07 1.00E-07
X/X 128 91.14
X/1 72 87.81 0.5 0.39–0.65
1/1 8 29.05 0.26 0.15–0.42
DELETERIOUS HAPLOTYPE: A30Cw5B18DR3DQ2
A 2.20E-01 2.00E-03 1.20E-03
X/X 102 131
X/30 86 62 1.54 1.17–2.03
30/30 17 12 2.37 1.36–4.10
Cw 2.50E-01 2.00E-03 1.26E-03
X/X 97.02 125.86
X/5 81.02 60.65 1.49 1.16–1.91
5/5 26.96 18.49 2.20 1.33–3.65
B 6.00E-03 1.80E-05 1.78E-05
X/X & X/18 170 195
18/18 35 10 4.01 2.13–7.58
DR 9.50E-01 1.00E-03 1.30E-03
X/X 94 119.7
X/3 80 67.5 1.50 1.17–1.91
3/3 31 17.8 2.34 1.37–3.64
DQ 2.40E-01 1.00E-03 9.20E-04
X/X 74 104.14
X/2 98 77.90 1.51 1.18–1.93
2/2 33 22.96 2.28 1.40–3.72
LRT p=p-value of the Likelihood Ratio Test for testing departure from a multiplicative model;
REG p=unadjusted p-value of an unconditional logistic regression;
EMPIRICAL p=empirical p-value of the logistic regression obtained after permutation;
X refers to all alleles other than the one taken into consideration.
doi:10.1371/journal.pone.0006526.t001
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primarily associated (see the paragraph ‘‘Analysis of the ancestral
haplotypes’’). For this analysis we used UNPHASED with the
condition option together with the tag options just described.
Conditioning on the B58 locus does not significantly change the
SNP specific p-value, whereas conditioning on DQ does and some
SNPs become not significantly associated with MS. After
conditioning, the genes, in which the statistically significant SNPs
are located, are NOTCH4, BTNL2, ITPR3 and PACSIN1 HLA-
DOB and TAP2 (supporting material S7).
Discussion
We carried out a family based association study to further
investigate the role of HLA region (on Chromosome 6p21) in MS
susceptibility. The contribution of HLA genes in MS pathogenesis
is well established. Nowadays the association of MS with the HLA-
DR2 haplotype, comprising the HLA-DRB1*1501 and HLA-
DRB5*0101 alleles, is the most replicated result among very
different populations and a biological explanation was recently
found for the strict co-occurrence of these alleles. DR2b protein
(encoded by HLA-DRB1*1501) in fact promotes a strong immune
response, while DR2a protein (encoded by HLA-DRB5*0101) has
an opposite and regulatory effect, inducing apoptosis of T cells.
Both proteins participate in the immune response modulation and
their interaction is a typical example of epistasis [48]. We choose
to analyse the isolated population of Nuoro, Sardinia, which is
characterised by a very high prevalence of MS (4–5 times higher
than the Italian mainland) and by a small number of very frequent
HLA haplotypes. The two most frequent HLA haplotypes are
A30Cw5B18DR3DQ2 (14.6%) and A2Cw7B58DR2DQ1 (6%) which
for their frequency are considered ancestral. To date, research on
MS in Sardinia has been mainly focusing on the most frequent
HLA ancestral haplotype and only on loci A, B, DR [36–38]. We
have gone a step forward and collected information also on the Cw
and DQ loci and hence we were able to consider the ‘‘entire’’
haplotype from A to DQ. We studied both A30Cw5B18DR3DQ2
and A2Cw7B58DR2DQ1.
We were able to refine Bitti’s results [37] as we found that
A30Cw5B18DR3DQ2 increases the risk of MS. B18 is confirmed to
be the most predictive single locus haplotype among Class I loci,
while for Class II both DR3 and DQ2 are positively associated:
however we can’t differentiate between them as they are in a
strong LD with each other.
Moreover, we found the second most frequent haplotype
A2Cw7B58DR2DQ1 to be protective. This result represents an
interesting novelty regarding the association between the HLA
alleles and MS. Locus B (B58) is again the most significant single
allele among Class I loci, while DQ1 among Class II loci.
As both Class I and Class II loci turned out to be associated with
MS, we based our subsequent analysis on investigating whether
they are associated independently. We confirmed previous results
[31,49] of Class I loci having an independent effect on the risk of
developing MS. Indeed our findings seem to support the claim that
both Class I and Class II loci have an effect on MS susceptibility,
but that they act independently from each other. The signal we
found for Class I loci still exist even when conditioning on Class II
loci and when taking LD into account. From a biological
perspective this makes sense, as HLA Class II molecules are
involved in the triggering of adaptive immune response and are
expressed by Antigen Presenting Cells (APC), while HLA Class I
Table 2. Sole variant and independent test carried out within the Class I and Class II loci of both protective and deleterious
haplotype.
CLASS I LOCI-Sole variant and independent test
Protective Ancestral Haplotype Deleterious Ancestral Haplotype
Test Model 1 Model 2 LRT Empirical p Model 1 Model 2 LRT Empirical p
Sole Variant* A2+Cw7+B58 B58 8.5E-1 A30+Cw5+B18 B18 4.0E-1
Independent** A2+Cw7+B58 A2+Cw7 4.0 E-4 A30+Cw5+B18 A30+Cw5 5.0E-4
CLASS II LOCI- Sole variant test and independent test
Protective Ancestral Haplotype Deleterious Ancestral Haplotype
Test Model 1 Model 2 LRT Empirical p Model 1 Model 2 LRT Empirical p
Sole Variant* DR2+DQ1 DQ1 7.4E-1 DR3+DQ2 DQ2 4.9E-1
Independent** DR2+DQ1 DR2 1.0E-3 DR3+DQ2 DR3 2.9E-1
LRT EMPIRICAL p=empirical p-value of the likelihood ratio test obtained after permutation;
*comparison of a model including both ‘everything else’ and the
‘particular variant’ with a model including the ‘particular variant’. If the p-value for the LRT is not statistically significant the particular variant is the ‘sole variant’.
**Comparison of a model in which ‘everything else’ and the ‘particular variant’ are included with a model including ‘everything else’. If a p-value for the LRT is statistically
significant, then this particular variant is associated independently on everything else.
doi:10.1371/journal.pone.0006526.t002
Table 3. Conditional Independence Test: comparison of the
model including both variants and the model including just
one of the sole variants within the deleterious and the
protective haplotype.
Conditional independence test
Protective Ancestral Haplotype Deleterious Ancestral Haplotype
Model 1 Model 2 LRT Empirical p Model 1 Model 2 LRT Empirical p
B58+DQ1 B58 9.7 E-5 B18+DR3 B18 1.9E-1
B58+DQ1 DQ1 7.7 E-4 B18+DR3 DR3 1.0E-4
LRT EMPIRICAL p=empirical p-value of the likelihood ratio test obtained
after permutation.
doi:10.1371/journal.pone.0006526.t003
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all nucleated cells. CD8+T cells are of central importance in lesion
pathogenesis as they outnumber CD4+T cells in MS lesions [46].
Moreover, HLA Class I molecules are ligand for the KIR (Killer
cell immunoglobulin-like receptors) protein family, expressed by
Natural Killer (NK) cells in different combinations and
amounts[50]. The role of NK cells in MS pathogenesis is
controversial as they promote both deleterious and protective
effects on neuronal cells[51]. Not much is known on the biological
function of KIR receptors and for now no direct connection has
been seen between KIR genes and MS. However, they cluster on
Chromosome 19q13.4, a region previously found in linkage studies
to be associated with MS[52].
To further enrich our study, we finally performed an
exploratory analysis on a set of 796 SNPs in the same HLA
region. Genomic regions containing SNPs associated with MS
were investigated using Ensembl genome browser Release 50 at
www.ensembl.org and HapMap - Phase 3 release data at www.
hapmap.org. The bioinformatic screen showed that the majority of
SNPs lie in genes with biological functions related to immune
response or to neuronal signal transmission. This analysis does not
add conclusive evidence in favour of any of these genes, given its
exploratory nature, however NOTCH4, BTNL2 and BAK1 deserve
some remarks. The NOTCH gene family participates in the control
of myelination and T cells commitment. Previous studies indicate
that developmental signal transduction pathways, involving
NOTCH1 (Neurogenic locus notch homolog protein 1)activation,
are re-expressed in damaged neurons in MS. The effect of this
signalling is the inhibition of remyelination, which is restored after
NOTCH1 inhibition [53]. Besides, NOTCH1 controls the differen-
tiation of naı ¨ve T CD4+cells into T helper type 1 (Th1) cells. Th1
lymphocytes have a central role in immune response towards
intracellular pathogens and their aberrant activity has been
associated to the induction of certain autoimmune diseases, MS
included [54].
NOTCH1 directly inhibits the expression of T-box transcription
factor TBX21, that encodes a transcription factor necessary to
Th1 maturation [55]: as a consequence, Th1 maturation is
inhibited [56]. NOTCH proteins are thus interesting because their
inhibition should provide a double beneficial effect against MS,
promoting remyelination and decreasing the number of Th1 cells.
BTNL2 is a negative regulator of T cell proliferation. Some
variants of BTNL2 and NOTCH4, different from those here tested,
have been found associated with MS in two studies, but in both
cases the association observed was considered secondary to HLA
DR15 influence [57,58]. BAK1 accelerates apoptosis, contrasting
the antiapoptotic molecule B-cell CLL/lymphoma 2 (BCL2).
Apoptosis is an important feature in MS pathogenesis. Deregu-
lation of this process can in fact promote both the survival of an
excessive number of auto-reactive immune cells and the death of
oligodendrocytes [59]. Nevertheless, apoptosis is necessary to
physiological oligodendrocytes maturation [60].
However, as this was just an exploratory analysis, with many
untyped data which were imputed conditioning on HLA loci, these
last results need to be confirmed both on our population and
replicated in others. Still, it appears that studying HLA main loci
only could not be enough as other HLA genes may be involved and
this could open new perspectives on the study of MS. In this
perspective, Sardinia and especially the Nuoro population provide
an important contribution. Indeed, the general population of
Sardinia has been shown to have similar levels of LD to outbred
populations, while isolated villages within Sardinia have substan-
tially increased levels of LD compared to cosmopolitan popula-
tions. The province of Nuoro is one of the oldest isolates founded
over 3000 years ago. The subsequent isolation of this area has
likely contributed to its divergence from the other European
populations in terms of allele frequencies, yet its age has afforded
many opportunities for recombination to occur between markers.
Service et al. [61] suggest that, considering the length of the LD
maps only, the association analyses in samples from Sardinia
would require at least 30% fewer markers than studies in outbred
population. For this reason, in this first part of the study LD helps
us to identify, more easily, the region which contains the genes
associated with MS but fine mapping is harder as a result and the
power of our conditional tests is affected by the strong LD in this
population.
Supporting Information
Supporting Material S1 Ancestral haplotypes.
Found at: doi:10.1371/journal.pone.0006526.s001 (0.03 MB
DOC)
Supporting Material S2 HLA typing, SNP typing and quality
control; % Call rate; SNP genotyping.
Table 4. Association between B, DR and DQ loci with MS.
Locus Alleles Pseudocases Pseudocontrols REG Empirical p
B5 32 36 NS
u 81 76 NS
12 25 22 NS
14 28 32 NS
18 159 112 6.74E-04
21 38 38 NS
22 81 3 N S
35 39 51 NS
58 16 46 1.93E-04
All B alleles - - - 1.8E-04
DR 1 22 23.30 NS
2 50 84.80 1.93E-04
3 150 108.00 5.78E-04
4 78 71.30 NS
5 58 52.50 NS
6 24 39.80 NS
7 18 25.30 NS
8 21 9.72 NS
10 5 11.60 NS
All DR alleles 2.33E-07
DQ 1 92 152 7.00E-09
2 173 131 3.85E-04
3 141 133.0 NS
4 20 10.5 NS
All DQ alleles 2.72E-08
The table reports the number of pseudocases and pseudocontrols and
empirical p-value of the alleles. Alleles are tested against all other alleles in the
same class Bu contains the alleles (7,8,13,15,16,27,37,40) that have a
frequency,4%.
REG Empirical p=empirical p-value of the logistic regression obtained after
permutation.
NS=Not Significant.
doi:10.1371/journal.pone.0006526.t004
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Class I and Class II alleles in pseudocases, pseudocontrols and in
the whole population.
Found at: doi:10.1371/journal.pone.0006526.s003 (0.04 MB
DOC)
Supporting Material S4 Effect of Class I locus adjusted for the
effect of the Class II locus, OR and its 95% CI.
Found at: doi:10.1371/journal.pone.0006526.s004 (0.03 MB
DOC)
Supporting Material S5 Empirical p-value for the null
hypothesis of association for the alleles at the B,DR and DQ loci
after conditioning for ancestral haplotypes alleles.
Found at: doi:10.1371/journal.pone.0006526.s005 (0.04 MB
DOC)
Supporting Material S6 MS and SNPs with tag markers alleles
composing the protective ancestral haplotypes: significant findings
reported.
Found at: doi:10.1371/journal.pone.0006526.s006 (0.04 MB
DOC)
Supporting Material S7 MS and SNPs with tag markers alleles
composing the deleterious ancestral haplotypes: significant findings
reported.
Found at: doi:10.1371/journal.pone.0006526.s007 (0.05 MB
DOC)
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